AI Virtual Screening & Structure‑Based Hit DiscoveryDrug Discovery

Atomwise: The AI Powering Smarter Small Molecule Discovery New

Claim it Now!
Atomwise - ai solutions in healthcare

Overview: Atomwise AI Drug Discovery Company Transforms Pharma R&D Atomwise’s AI‑driven drug discovery platform applies deep learning to predict how small molecules are likely to bind to protein targets, helping discovery teams move from broad chemical libraries to focused sets of plausible hits much earlier in the pipeline. Instead of relying solely on high‑throughput, trial‑and‑error […]

Feature Categories

Overview: Atomwise AI Drug Discovery Company Transforms Pharma R&D

Atomwise’s AI‑driven drug discovery platform applies deep learning to predict how small molecules are likely to bind to protein targets, helping discovery teams move from broad chemical libraries to focused sets of plausible hits much earlier in the pipeline. Instead of relying solely on high‑throughput, trial‑and‑error screening, Atomwise scores and prioritises compounds in silico, allowing chemists and biologists to concentrate experimental resources on candidates with a stronger chance of meaningful activity and better starting properties for optimisation. In therapeutic areas where conventional screening has produced long timelines and high attrition, this front‑loaded, model‑guided approach aims to surface higher‑quality options faster and with greater confidence.

For R&D organisations, the platform functions as a virtual screening and design engine that slots into existing project workflows, from target assessment through hit identification and lead refinement. Teams can use Atomwise’s predictions to shape which compounds they synthesise and test, explore novel chemotypes around a target, and iteratively improve series by feeding back experimental results into the modelling loop. By compressing cycles of design–make–test–analyse, and by reducing the proportion of dead‑end chemistry, Atomwise is designed to shorten early discovery timelines, free up budget and lab capacity for more ambitious programmes, and improve the likelihood that projects advancing toward preclinical development are supported by stronger, data‑driven evidence rather than historical precedent alone.

What is Atomwise?

Atomwise is a pioneering artificial intelligence tool designed to enhance the drug discovery process, particularly for small‑molecule programmes in pharma and biotech. In a prospective 318‑target study spanning 22 internal pharma programs and 296 academic projects, AtomNet‑guided campaigns achieved project‑level hit identification in 73–75% of targets, with average hit rates around 5–7.6%, positioning AtomNet as a viable replacement for traditional high‑throughput screening as the first step in small‑molecule discovery. [1]

Utilising deep learning technologies, its AtomNet® model powers Atomwise AtomNet virtual screening workflows that analyse 3D protein–ligand interactions to predict which compounds are most likely to bind and show bioactivity, based on training across millions of historical measurements.​
Atomwise’s platform accelerates lead identification by ranking focused sets of tens to low hundreds of compounds from virtual screens that can span billions of candidates, rather than relying on brute‑force physical screening of very large libraries.

In a large 318‑target validation effort, AtomNet‑guided campaigns reported project‑level hit identification in roughly three‑quarters of targets tested, including many in oncology and infectious disease, illustrating its relevance for complex disease areas.
By providing ranked hypotheses and experimentally tractable hit lists, Atomwise enables researchers to make data‑driven decisions earlier in discovery, with published studies reporting single‑digit percentage hit rates on experimentally tested compounds compared with the much lower hit rates typical of plate‑based high‑throughput screening. Critically, for first‑in‑class programmes, 70% of the 296 academic targets in that study had no prior on‑target actives in the training data, yet AtomNet still delivered a 75% project success rate with a 5.3% average hit rate, statistically indistinguishable from targets with rich historical data. [2]

Atomwise Rebrand Numerion Labs

Atomwise AI drug discovery company overview. Atomwise effectively rebranded into Numerion Labs around October 2025.  In practical terms, this means Atomwise’s technology, team, and programs now continue under the Numerion Labs name, with a strategic focus on ultra-fast virtual screening (APEX) and immune/inflammatory disease programs. [3]

Why Leading Healthcare Teams Trust Atomwise

  • Signed a multi‑target AI drug discovery collaboration with Sanofi that included around $20 million in upfront and near‑term payments and up to approximately $1.2 billion in potential milestones and royalties, all centred on using AtomNet® to screen very large virtual libraries against a small number of high‑value targets.

  • Atomwise ranked among the Top‑10 in Biotechnology on Fast Company’s “World’s Most Innovative Companies” list, recognised for pioneering deep‑learning‑based small‑molecule discovery through its AtomNet® platform and large‑scale collaborations with academia and industry​

  • Atomwise has expanded AI-driven drug discovery partnerships with Chinese biopharmaceutical company Hansoh (Jiangsu Hansoh Pharmaceutical Group), indicating traction with established Asian pharma actors in oncology and other therapeutic areas.​

  • Atomwise has entered multiple collaborations and joint ventures with pharmaceutical and biotechnology partners to apply its AI platform across diverse therapeutic pipelines, demonstrating repeat commercial uptake of its technology rather than one-off pilots.​

  • Launched the AIMS Awards, supporting hundreds of academic and non‑profit research projects worldwide by providing AI‑powered virtual screening and compound predictions; a recent AIMS‑based study reported 318 prospective screening projects involving 482 labs at 257 institutions across 30 countries, with billions of protein–small‑molecule interactions evaluated computationally.​

  • Academic users of the AIMS program, such as UNC’s drug discovery unit, have reported that Atomwise’s AI predictions for small-molecule binding aligned strongly with subsequent medicinal chemistry and screening results, suggesting technical robustness in real-world research settings.​

  • Atomwise has raised approximately 123 million USD in a Series B round (around 175 million USD total capital raised at that time) to scale its AI drug discovery platform, indicating backing from institutional investors and associated due diligence on technology and operations.​

  • The strategic Sanofi collaboration is structured with substantial milestone and royalty components, placing Atomwise under long-term performance expectations and creating incentives for ongoing platform reliability and scientific delivery rather than short-term projects.​

  • Public materials and third-party coverage predominantly describe Atomwise as an AI-enabled drug discovery partner rather than a marketed clinical decision support or diagnostic device, and there is no evidence of FDA clearances, CE marking, or specific HIPAA/ISO certifications, indicating that hospitals would primarily interact with it as an R&D partner rather than a regulated medical device vendor.

  • Collaborates with leading industry players, including Eli Lilly, Bayer, GC Pharma, Hansoh Pharmaceuticals, and Bridge Biotherapeutics, via multi‑programme discovery collaborations and joint ventures that together represent several billion dollars of potential deal value across oncology, immunology, infectious diseases, and other therapeutic areas.

  • AI Tool Overview Video: Atomwise

Video Transcript Summary of Key Points

  • Computational Necessity: As the chemical space for potential drugs grows from millions to billions of molecules, “brute-forcing” physical tests is no longer feasible; early experiments must be done computationally with high accuracy.

  • Deep Learning Innovation: Atomwise invented the application of convolutional neural networks (CNNs)—the same technology used in facial recognition and self-driving cars—to the domain of biochemistry for molecular recognition.

  • The AtomNet Model: Their core technology, AtomNet, uses deep learning on 3D structural models of proteins and small molecules to predict whether a specific compound will bind to a target protein.

  • Tackling “Dark Targets”: Because the model learns the underlying physics of biophysical interactions, it can make predictions for “dark targets” (proteins with no known binding partners) where traditional machine learning might fail.

  • Scale and Parallelism: The AI allows for the screening of billions of molecules in parallel across various diseases, significantly increasing the efficiency and breadth of drug discovery compared to traditional tools.

Top 3 Pain Points Addressed By Atomwise

This table outlines the top three problems in drug discovery and early development that Atomwise addresses, and explains how its AtomNet deep learning technology mitigates each issue. It links specific pain points—such as slow molecule screening, difficulty targeting “dark” proteins, and low hit quality—to the platform’s virtual screening and data‑driven prediction capabilities
Problem it SolvesHow Atomwise Solves It
Slow, brute‑force screening of candidate molecules. [4]Atomwise uses AtomNet, a deep learning model, to virtually screen very large chemical libraries and predict which small molecules are most likely to bind a target protein, reducing the need to physically make and test every prototype.
Inability to explore “dark” or poorly understood targets. [5]By learning general physicochemical patterns of protein–ligand interactions, AtomNet can propose binders for targets with little or no prior ligand data, enabling exploration of novel or previously neglected proteins.
Low hit quality from noisy and heterogeneous biological dataAtomwise curates large, diverse structural and biological datasets to train AtomNet, improving prediction accuracy so that virtual hits are more likely to translate into viable leads when synthesized and tested in the lab.

Feature Category Summary: Atomwise

This table summarises how Atomwise aligns with a set of predefined feature categories by providing brief evidence‑based descriptions in the “Summary” column and indicating, in the “Association (YES, NO, NA)” column, whether each feature is meaningfully associated with the platform
Feature CategorySummaryAssociation (YES, NO, NA)
Regulatory-ReadyPublic materials describe Atomwise as an AI screening and discovery partner but do not document 21 CFR Part 11 / GxP controls, validated audit trails, or formal FDA/EMA compliance features in the platform itself; no regulatory filings or validation white papers are available for AtomNet as a regulated system. ​NA
Clinical Trial SupportAtomwise positions its technology in early discovery and preclinical hit/lead optimization; there is no evidence that the platform provides trial design, patient recruitment, monitoring, or clinical reporting modules. ​NA
Supply Chain & QualityNo documentation indicates functionality for manufacturing QA, GMP batch control, serialization, or counterfeit detection; Atomwise’s scope is in silico screening and discovery, not supply chain operations. ​NA
Efficiency & Cost-Saving. [6]Automates and accelerates early discovery by shifting from screening millions of physical compounds to testing focused sets derived from virtual screens over billions of candidates, reducing assay load and wasted screening capacity. YES
Scalable / Enterprise-Grade. [7]Atomwise reports collaborations with numerous pharmaceutical, biotech, and academic partners and uses cloud infrastructure (e.g., AWS, WEKA) to run large‑scale virtual screens, indicating enterprise‑grade scalability for big discovery programs, but without formal SaaS multi‑tenant governance details. ​YES
HIPAA CompliantThere is no indication that Atomwise manages protected health information, targets clinical workflows, or claims HIPAA or equivalent health‑data privacy compliance; its inputs are chemical and target data rather than patient‑level clinical records. ​NA
Clinically Validated. [8]Articles note that Atomwise‑identified compounds, such as a TYK2 inhibitor, are being advanced toward or into clinical trials, but there is no evidence that the AtomNet platform itself has undergone formal clinical validation as a medical device or CDSS; the validation is at the molecule/program level, not as a clinical tool. NA
EHR IntegrationNo public documentation shows integration with EHRs, clinical data warehouses, or health IT standards (FHIR, HL7); Atomwise is presented as a discovery engine, not a clinical data system. ​NO
Explainable AIAtomNet is described as a deep learning model for binding‑affinity prediction that delivers ranked compound lists and structure‑based insights, but there is no explicit mention of XAI methods (feature attribution, saliency maps, reason codes) or user‑facing explainability tooling; explanations, if any, are generic to structure‑activity relationships rather than documented XAI features. ​NO
Real-Time AnalyticsThe platform performs high‑throughput virtual screening and large offline computation; there is no claim of real‑time streaming analytics or live monitoring dashboards comparable to clinical or operational systems. ​NO
Bias DetectionThere is no public description of systematic bias detection, fairness metrics, or subgroup performance analysis in AtomNet’s models; discussions focus on screening performance and hit rates, not demographic or cohort bias (which is also less central in small‑molecule docking use cases). ​NO
Ethical SafeguardsPublic sources do not describe built‑in governance tools such as consent management, use‑case restriction controls, human‑in‑the‑loop review frameworks, or alignment with specific AI ethics standards; ethics is discussed at a high level, if at all, rather than as implemented safeguards in the platform. ​NO

Atomwise Features

This table provides a structured overview of Atomwise, detailing its category, commercial model, technical capabilities, and typical deployment patterns in drug discovery. It summarises how the platform is used by pharma and biotech organisations, what data and use cases it supports, and where it fits relative to competing AI-driven discovery tools.
FieldValue
CategoryAI-driven small molecule drug discovery; virtual screening; preclinical pharma R&D.
Pricing Model
  • Collaboration-based agreements with upfront payments and research funding.
  • Development and commercial sales milestones tied to program progress.
  • Tiered royalties on products originating from AI-derived compounds.
  • Per-target evaluation or technology-access agreements for some partners.
Type (e.g., Demo, Paid, Freemium, Contact for Pricing)Contact HealthyData for Pricing
Typical pricing range or “Not specified”Not specified
Typical deployment/pricing scenarios (brief)
  • Multi-target alliances with large pharma, combining an upfront payment with substantial potential R&D and commercial milestones plus royalties.
  • Per-target discovery collaborations with milestone payments linked to hit identification, lead optimization, and preclinical advancement.
  • Strategic partnerships where the vendor supplies AI-driven hit discovery and partners fund medicinal chemistry and development.
Supported Data Types
  • 3D protein structures and binding-site models (e.g., X‑ray, cryo‑EM, homology models).
  • Small-molecule structures and large virtual or synthesis-on-demand compound libraries.
  • Structure-based bioactivity data and assay readouts (hit labels, potency values) for training and validation.
  • Partner-supplied preclinical data such as biochemical and cell-based assay results and SAR series.
Deployment Model
  • Cloud-based high-performance computing platform using GPU-accelerated infrastructure.
  • Managed collaboration/service model operated by the vendor’s scientific teams rather than self-service SaaS.
  • Containerized and orchestrated virtual screening workflows suitable for large-scale vHTS.
Key Use Cases (Healthcare & Life Sciences)
  • Virtual high-throughput screening of very large compound libraries to identify hit compounds for novel or challenging targets.
  • Discovery of structurally novel scaffolds and first-in-class binders for targets without known non-covalent ligands.
  • Hit-to-lead and early lead optimization support by prioritizing analogs for predicted potency, selectivity, and developability.
  • Portfolio expansion and triage by rapidly exploring synthesis-on-demand chemical space beyond the reach of physical HTS.
  • Support for oncology, inflammatory, infectious, and neurological disease programs through structure-based design.

Real-life success story: In a large multi-target initiative with academic collaborators, the platform was used as a primary virtual screen across more than three hundred diverse protein targets. Confirmed hits were obtained for the majority of targets, often including several distinct chemotypes per target and first-in-class binders where no non-covalent ligands had previously been identified. Reported hit rates and overall project success rates were comparable to or better than typical physical high-throughput screening. This demonstrated that AI-driven virtual screening could function as a practical alternative to conventional HTS for early discovery across many target classes and disease-relevant pathways.
Target Users
  • Medicinal chemistry and small-molecule discovery teams in large pharmaceutical companies.
  • Computational chemists, structural biologists, and in silico screening groups.
  • Preclinical and translational R&D leaders in mid-sized pharma and biotech.
  • Academic and non-profit investigators involved in AI-enabled virtual screening collaborations.
Integration & Compatibility
  • Integrates with discovery workflows via secure exchange of protein structures, compound lists, and assay data.
  • Operates on standard cloud compute and storage infrastructure compatible with common research IT environments.
  • No documented direct integration with EHR, LIS, PACS, HL7, FHIR, or DICOM; focus is on research and preclinical discovery data.
Scalability / Capacity
  • Virtual screening of tens to hundreds of millions of compounds per day in typical large campaigns.
  • Access to ultra-large chemical libraries extending into quadrillions of synthesizable molecules.
  • Architecture designed for high concurrency and very large discovery datasets across multiple simultaneous partner programs.
Therapeutic Area Focus
  • Cross-therapeutic; not limited to specific disease areas.
  • Documented applications in oncology, inflammatory and autoimmune disease, infectious disease, and neurology.
Unique AI Model Capabilities
  • Deep 3D convolutional neural network for structure-based prediction of binding affinity and bioactivity.
  • Can identify hits even when no target-specific actives are present in training data, enabling discovery on data-poor or previously undruggable targets.
  • Virtual screening across ultra-large synthesis-on-demand libraries far exceeding typical physical HTS collections.
  • Demonstrated ability to find multiple distinct chemotypes per target, including first-in-class binders.
  • Prospective studies reporting hit and project success rates comparable to or better than conventional HTS.
Operational & Financial Impact
  • May reduce dependence on costly physical high-throughput screening by shifting early hit discovery to virtual campaigns; exact cost savings are not publicly quantified.
  • Can shorten early discovery timelines by prioritizing compounds and focusing experimental work on high-likelihood hits; precise time savings are not consistently reported.
  • Discovery of novel chemotypes and first-in-class binders can improve the probability of differentiated clinical candidates and strengthen IP positions, though portfolio-level metrics are limited.
  • Large milestone-based collaborations with major pharma companies indicate substantial perceived strategic and financial value, but detailed ROI remains confidential.
    • [9]
Competitive Comparisons
  • Exscientia – AI-driven small molecule design with strong closed-loop design–make–test cycles and an internal clinical pipeline alongside partnerships.
  • BenevolentAI – Uses knowledge graphs, omics, and clinical data for target identification and indication expansion across the discovery pipeline.
  • Schrödinger – Focuses on physics-based and ML-augmented molecular modeling and simulation, typically delivered as licensed software plus services rather than primarily virtual HTS.
  • Insilico Medicine – Applies generative models for target discovery and de novo molecule design, with a strong internal pipeline in addition to collaborations.
Deployment Time and Ease of Use
  • Onboarding large collaborations usually requires negotiation of research, IP, and data-sharing agreements and program design; typical timelines are weeks to months.
  • Operational use is managed largely by the vendor’s computational and medicinal chemistry teams, limiting UI burden for partners but requiring close scientific coordination.
  • Partner effort focuses on target selection, provision of structural and assay data where available, and integration of AI-derived hit series into existing discovery workflows.
User Ratings and SourceUser ratings: Not specified
Industry Fit (Enterprise vs Mid-market vs Start-up)
  • Strong fit for large pharma enterprises seeking AI-augmented discovery across multiple therapeutic areas.
  • Suitable for mid-sized pharma and biotech through focused multi-program collaborations.
  • Collaborations with academic and non-profit groups indicate good fit for early-stage and translational research.
Website Linkhttps://www.atomwise.com/

Evidence & Validation: Atomwise

Summary of available clinical, technical, and operational validation evidence for Atomwise across healthcare and life sciences drug discovery contexts:

 

Evaluation type: Large, multi-target prospective virtual screening study comparing AI-based screening with traditional high-throughput screening (HTS). Population/setting: 318 small-molecule discovery projects across more than 250 academic laboratories and partners, spanning diverse therapeutic areas and protein classes. Key outcomes: AtomNet achieved project‑level success in roughly three‑quarters of the 318 campaigns, with average hit rates of 5–7.6% on experimentally tested compounds and 51% confirmation in follow‑up dose–response assays, all while operating at substantially lower false‑positive rates than plate‑based HTS, which can reach ~95%. [10]

 

Evaluation type: Technical validation of convolutional neural network–based structure‑based virtual screening for novel chemical scaffolds. Population/setting: Computational screening campaigns against targets lacking known binders, high‑quality crystal structures, or manually curated compound sets, using large commercial libraries of small molecules. Key outcomes: Across these campaigns, compounds selected for synthesis were constrained to have Tanimoto similarity <0.5 to any known active in the training data, and for the ~70% of targets with no actives at all the resulting hits had zero training‑set similarity, demonstrating true novel‑scaffold discovery rather than incremental analoguing of prior art. [11]

 

Evaluation type: Operational performance and partnership outcomes in industry collaborations. Population/setting: Pharmaceutical and biotechnology partnerships using Atomwise’s platform for hit identification and early discovery programs across multiple therapeutic areas. Key outcomes: Public partnership reports describe successful identification of hit series and progression into further optimisation in a substantial proportion of partnered programs; however, detailed GxP validation, downstream clinical impact, and formal regulatory qualification data are not yet comprehensively reported in the public domain.

Evidence and Further Reading (for Due Diligence Teams)

Infrastructure & data‑scale details (Atomwise + WEKA + AWS) AI‑based Drug Discovery with Atomwise and Weka on AWS – WEKA blog/solution story. Describes AtomNet® as built on best‑in‑class engineering tools with WEKA, NVIDIA and AWS as key partners, and details the data challenges (around 4,000 protein structures, 3 million compounds, ~15 million experiments and ~30 million training files) and how the WEKA data platform supports the bursty, GPU‑intensive workloads used in Atomwise’s virtual screening pipelines. [12]

Intended Use and Context

Atomwise is intended for use by pharmaceutical, biotechnology, and academic R&D teams to support early‑stage small‑molecule drug discovery, including virtual screening, hit identification, and lead optimisation across diverse therapeutic areas. It is designed to augment, not replace, professional scientific, clinical, safety, or regulatory judgment and is not intended to function as an autonomous diagnostic or clinical decision‑making system. Any deployment must comply with applicable research, GxP, medical device, and data‑protection regulations and align with the organisation’s governance, validation, and quality‑management processes. Specific regulatory clearances or approvals for Atomwise’s platform are not specified in publicly available documentation.

Why This Shift Matters Now​

As of early 2026, industry tracking shows more than 170 AI‑discovered drug programmes in clinical development, up from only 3 in 2016, with multiple platforms—including AtomNet‑enabled pipelines—now supplying candidates that are entering mid‑stage trials. [13]

AI in drug discovery is also reaching a tipping point: market analyses project the space to grow from a mid‑single‑digit billion‑dollar segment in the mid‑2020s to well over $15 billion by the early 2030s, with the vast majority of large pharma companies reporting active investment in AI‑enabled R&D. That means the question for most organisations is not whether to explore AI for discovery, but how to choose platforms that are already being used at scale in pharma‑grade contexts. [14]

Most pharma organisations are now experimenting with AI somewhere in their pipeline, but relatively few have moved beyond proof‑of‑concept into production; this page is designed to help you evaluate whether a platform like Atomwise can be part of that transition. [15]

Risk and Limitations: Atomwise

Summary of key implementation, adoption, and governance risks for Atomwise in AI‑enabled small‑molecule drug discovery, including configuration gaps, data quality issues, integration dependencies, user adoption, and the need for ongoing compliance oversight.

  • Predictive ranking and virtual screening performance depend heavily on the quality, representativeness, and curation of underlying structural and assay data; biased, noisy, or incomplete datasets can lead to misleading hit lists or missed chemotypes.

  • Model behaviour may not generalise to novel targets, chemotypes, or experimental conditions that differ from the training distribution, and configuration gaps in target preparation or library selection can further reduce performance.

  • Integration with existing cheminformatics, ELN, HTS, or data‑management platforms may require significant IT effort, secure data pipelines, and change management to ensure consistent workflows and auditability.

  • Outputs are intended to support, not replace, expert scientific, safety, or regulatory judgment; over‑reliance on AI scores without cross‑checking experimental data and medicinal chemistry input can lead to suboptimal program decisions.

  • Effective user adoption depends on clear ownership, training, and documentation; inconsistent use across project teams can result in fragmented records, duplicated experiments, or limited learning from prior campaigns.

  • Use of Atomwise outputs in regulated contexts (such as GxP‑relevant development decisions or regulatory submissions) may require additional validation, documentation, and governance aligned with evolving AI‑in‑drug‑development guidance and internal quality‑risk frameworks.

  • Model generalisability varies by target class; while protein families with extreme flexibility or poorly defined binding sites remain challenging, recent prospective data show that many protein–protein interactions and allosteric sites can achieve success rates above 70% when suitable structures are available

How This Page is Curated

The AI tool featured on this page is selected through independent research using healthcare and life sciences search data, vendor documentation, and public evidence on clinical and operational use. Each listing is evaluated using a consistent structure (intended use, evidence and validation, regulatory posture, risks and limitations), and updated periodically as vendors release new information.

Sponsorships may influence visibility (for example, ‘featured’ placements) but not the substance of our analysis or comparative rankings.

Atomwise - Frequently Asked Questions

Atomwise’s AtomNet platform has been evaluated in a 318‑target virtual screening study involving over 250 academic laboratories, reporting success rates around 74–75% and hit rates of ~5–6% even when no prior actives were available. These results suggest Atomwise can function as a viable alternative to traditional high‑throughput screening for early hit discovery, although downstream clinical and commercial impacts depend on each sponsor’s development program.

Deeper‑dive buyer FAQs for Atomwise

Want to stress‑test Atomwise on science, IP, integrations, and implementation risk? Read the buyer‑grade Atomwise FAQs that address common deal‑breaker questions before you talk to vendors.

Compare Atomwise with alternative AI solutions

Need to see how Atomwise stacks up against other AI options for your use case? Read the buyer‑grade comparison of Atomwise vs key competitors, focused on real deal‑breaker questions and due‑diligence criteria before you shortlist vendors.

Tags

Share This AI Tool

This listing for Atomwise first appeared on HealthyData.Science and in major search indexes, and is protected as original, unbiased, curated content.

Disclaimer: This listing is for information and discovery only. The AI tool and examples described here do not replace professional scientific, clinical, safety, or regulatory judgment, and any use in practice must follow your organisation’s own governance and validation processes.

Get a neutral, no obligation view of whether this AI tool fits your portfolio

Avatar

Stephen

Founder of HealthyData.Science · 20+ years in life sciences compliance & software validation · MSc in Data Science & Artificial Intelligence.
hello@healthydata.science
  1. Across 318 prospective experiments, the AtomNet platform identified novel hits for 73.9% of targets, achieving average hit rates of 6.7% for internal projects and 7.6% for academic collaborations. These results demonstrate that computational screening can effectively replace traditional high-throughput methods as the primary stage of discovery. Stearns, K., et al. (2024). Wide-spectrum prospective hit discovery with an artificial intelligence platform for drug discovery.[↩]
  2. In a study of 296 academic targets, 70% lacked prior on-target actives in training sets. Despite this, the platform achieved a 75% success rate and a 5.3% average hit rate, demonstrating that performance for novel targets remains statistically indistinguishable from those with extensive historical data. Stearns, K., et al. (2024). Wide-spectrum prospective hit discovery with an artificial intelligence platform for drug discovery.[↩]
  3. Atomwise is advancing its TYK2 inhibitor program toward clinical trials for inflammatory and autoimmune diseases. This transition from hit identification to IND-enabling studies demonstrates the company's capability to progress AI-discovered chemistry into formal clinical development rather than remaining limited to early-stage discovery. U.S. Biotech News Staff (2023). AI-Based Drug Discovery Company Atomwise Sets Its Sights on Inflammatory Disease Market.[↩]
  4. Prospective screening using the AtomNet platform yielded hit rates between 5.3% and 7.6%, representing a 50- to 760-fold increase over traditional high-throughput screening averages of 0.01% to 0.1%. This efficiency significantly reduces the number of physical assays required to identify high-quality lead compounds.Stearns, K., et al. (2024). Wide-spectrum prospective hit discovery with an artificial intelligence platform for drug discovery[↩]
  5. Analysis of prospective screening outcomes showed that AtomNet maintained consistent hit rates across various structural sources, achieving 5.6% with X-ray crystallography, 5.5% with cryo-EM, and 5.1% with homology models. This demonstrates high performance and minimal degradation when relying on modelled binding sites rather than experimental structures. Stearns, K., et al. (2024). Wide-spectrum prospective hit discovery with an artificial intelligence platform for drug discovery.[↩]
  6. AI-driven discovery platforms can reduce preclinical timelines by 30–50% and lower discovery-stage costs by 15–50%. The most significant financial and temporal gains occur when virtual screening narrows or replaces traditional high-throughput screening, optimising lead identification and reducing the volume of necessary physical assays. NanoGPT Staff (2024). AI in Drug Discovery: A Cost and Timeline Breakdown.[↩]
  7. The 318-target screening program utilised supercomputing-scale resources, computing over 20 billion protein-ligand scores. Individual virtual screens required more than 40,000 CPUs and 3,500 GPUs, involving 150 TB of RAM and 55 TB of data movement to manage the massive computational load. Stearns, K., et al. (2024). Wide-spectrum prospective hit discovery with an artificial intelligence platform for drug discovery.[↩]
  8. Clinical pipeline data reveals that AI-discovered small molecules achieve Phase I success rates between 80% and 90%, nearly doubling the 52% historical industry average. This suggests that AI-driven optimisation of drug-like properties and safety profiles significantly improves the quality of candidates entering human trials. Rodríguez-Pérez, R., et al. (2025). AI-discovered drugs: A performance review of the clinical pipeline.[↩]
  9. By screening multi-billion-compound libraries virtually and only testing a small number of AI-prioritized candidates, this workflow reduces preclinical timelines and R&D costs by up to 50%. This approach maintains high hit quality while significantly decreasing the physical resource requirements of early discovery. Stearns, K., et al. (2024). Wide-spectrum prospective hit discovery with an artificial intelligence platform for drug discovery.[↩]
  10. In a 318-target study, the platform achieved a 75% success rate with average hit rates of 5.3% to 7.6%. Furthermore, 51% of identified hits were confirmed in follow-up dose-response assays, demonstrating significantly higher precision and lower false-positive rates compared to traditional high-throughput screening. Stearns, K., et al. (2024). Wide-spectrum prospective hit discovery with an artificial intelligence platform for drug discovery.[↩]
  11. To ensure novelty, all synthesized compounds were restricted to a Tanimoto similarity of less than 0.5 against known actives. For 70% of targets with no previously documented actives, the platform identified successful hits with zero training-set similarity, confirming its ability to discover novel chemical scaffolds. Stearns, K., et al. (2024). Wide-spectrum prospective hit discovery with an artificial intelligence platform for drug discovery.[↩]
  12. To support its GPU-intensive virtual screening, Atomwise utilizes a high-performance infrastructure involving WEKA, NVIDIA, and AWS. This platform manages massive datasets, including 4,000 protein structures and 30 million training files, providing the necessary throughput and scalability for bursty, large-scale computational drug discovery workloads. Weka. (2022). AI-based Drug Discovery with Atomwise and Weka on AWS.[↩]
  13. Industry tracking through early 2026 identifies over 170 AI-discovered drug programs in clinical development, representing a significant increase from just three programs in 2016. Several AI-enabled pipelines have successfully advanced candidates into mid-stage clinical trials, demonstrating the increasing maturity of computational discovery platforms. Intuition Labs. (2024). Accelerating Drug Development: How AI is Reshaping the Pharma Industry.[↩]
  14. The global market for AI in drug discovery is projected to grow from 6.93 billion dollars in 2025 to over 16.5 billion dollars by 2034. This expansion is driven by pharmaceutical companies integrating machine learning to accelerate target identification and reduce R&D costs. BioSpace. (2024). Artificial Intelligence (AI) in Drug Discovery Market Size Expected to Reach USD 16.52 Billion by 2034[↩]
  15. While 60% of healthcare executives have transitioned AI initiatives beyond the pilot phase, most pharmaceutical organisations remain in the early stages of adoption. Scaling these technologies into production requires moving past fragmented proofs-of-concept toward integrated platforms that demonstrate measurable clinical and operational value. Bain & Company. (2024). The Healthcare AI Adoption Index[↩]